Bruker Guides FY26 Adj EPS to $2.10-$2.15, Below Consensus
BRKR has more than doubled off its 52-week low of $28.53.
Summary
Bruker initiated FY26 adjusted EPS guidance of $2.10-$2.15, which falls short of the $2.30 consensus. This follows a brutal Q1 where net income dropped 79.9% on restructuring charges and asset impairments. The guidance suggests the turnaround is taking longer than the Street expected. With a $9.8B market cap and shares at $59, the miss is material enough to force position adjustments. The company has an active S-3ASR shelf filed in June, adding potential dilution risk if capital needs arise.
At the time of this announcement, BRKR was trading at $59.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $28.53 to $65.30. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.